Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

1 clinical trials · Condition

Record	Firm	Date
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT03624036)	Kite, A Gilead Company	2018-11-15

Every clearance here is in the API, with alerts when new ones post.